Search research articles
Contact Us
Filters
Showing results (31-40 of 151) with videos related to
Page
of 16
Sort By:
Frontiers in Oncology
|
February 28, 2022
Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches
David W Cescon, Kevin Kalinsky, Heather A Parsons, et al.
Clinical Breast Cancer
|
October 2, 2019
Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer
Kathleen Fenn, Matthew Maurer, Shing M Lee, et al.
Clinical Breast Cancer
|
January 14, 2020
Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy
Madeleine B Hopson, Maika Onishi, Danielle Awad, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
August 29, 2024
Tuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs
Lidan Zeng, Yueming Zhu, Xin Cui, et al.
Journal of Oncology Practice
|
January 2, 2013
Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study
Grace Clarke Hillyer, Alfred I Neugut, Katherine D Crew, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 1, 2012
Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer
Heather Greenlee, Katherine D Crew, Theresa Shao, et al.
Integrative Cancer Therapies
|
November 20, 2025
Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment
Heather Greenlee, Katherine D Crew, Matthew Maurer, et al.
Breast Cancer Research and Treatment
|
June 21, 2024
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States
Kevin Kalinsky, Laura Spring, Clinton Yam, et al.
Breast Cancer Research and Treatment
|
May 5, 2018
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)
Jame Abraham, Robert Coleman, Anthony Elias, et al.
NPJ Breast Cancer
|
November 7, 2022
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Tao Qing, Thomas Karn, Mariya Rozenblit, et al.
Page
of 16
Search research articles
Search
Showing results (31-40 of 151) with videos related to
Sort By:
Page
of 16
Frontiers in Oncology
|
February 28, 2022
Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches
David W Cescon, Kevin Kalinsky, Heather A Parsons, et al.
Clinical Breast Cancer
|
October 2, 2019
Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer
Kathleen Fenn, Matthew Maurer, Shing M Lee, et al.
Clinical Breast Cancer
|
January 14, 2020
Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy
Madeleine B Hopson, Maika Onishi, Danielle Awad, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
August 29, 2024
Tuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs
Lidan Zeng, Yueming Zhu, Xin Cui, et al.
Journal of Oncology Practice
|
January 2, 2013
Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study
Grace Clarke Hillyer, Alfred I Neugut, Katherine D Crew, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 1, 2012
Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer
Heather Greenlee, Katherine D Crew, Theresa Shao, et al.
Integrative Cancer Therapies
|
November 20, 2025
Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment
Heather Greenlee, Katherine D Crew, Matthew Maurer, et al.
Breast Cancer Research and Treatment
|
June 21, 2024
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States
Kevin Kalinsky, Laura Spring, Clinton Yam, et al.
Breast Cancer Research and Treatment
|
May 5, 2018
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)
Jame Abraham, Robert Coleman, Anthony Elias, et al.
NPJ Breast Cancer
|
November 7, 2022
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Tao Qing, Thomas Karn, Mariya Rozenblit, et al.
Page
of 16